BioTech IP Review

Assignee: Illumina, Inc. (San Diego, CA, USA)
Filed: January 17, 2025
Patent Issued: October 7, 2025
Patent Publication Number: 20250163507
Inventors: Robert C. Kain, David L. Heiner, Chanfeng Zhao, Kevin Gunderson

---

What It Covers

This patent protects a next-generation nucleic acid sequencing system — a platform and method for sequencing DNA/RNA with improved performance, accuracy, and throughput. The invention reflects core innovations in sequencing hardware and associated methods that are essential to Illumina’s instruments, reagents, and workflows used across research, clinical diagnostics, and applied genomics.

Key elements of the invention include:

• Sequencing system architecture:
  The patent claims an integrated apparatus and workflow for reading and processing nucleic acid sequences, including components that generate, detect, and interpret fluorescent or optical signals from sequencing reactions.
• Signal processing and data resolution:
  Improvements likely focus on signal accuracy, error reduction, and real-time data handling — critical for next-generation sequencing (NGS).
• Instrument design:
  The inventors are credited with innovations in both hardware and software that enable high-density sequencing, efficient data capture, and robust performance across different sample types.

---

Why It’s Important

• Core proprietary platform

This patent protects foundational technology used in Illumina’s sequencing instruments, such as the NovaSeq, NextSeq, or future lines. These platforms generate the bulk of the company’s revenue and are central to research, clinical diagnostics, and biopharma development globally.

• Competitive moat in genomics

Sequencing systems are complex and expensive to develop. Patents on improved sequencing architectures and methods help Illumina defend against rivals (including litigation with 10x Genomics over spatial transcriptomics technologies) and maintain leadership in the genomics market.

• Broad market impact

Genomic sequencing drives personalized medicine, cancer profiling, rare disease diagnosis, pathogen surveillance, agricultural genomics, and more. Patents like this support long-term royalties from instruments, consumables, and services.

Summary

U.S. Patent No. 12,435,371 B2, granted October 7, 2025 to Illumina, Inc., covers a nucleic acid sequencing system — a foundational platform for reading genetic material with high precision and throughput. This patent is strategically important and potentially lucrative because it underlies Illumina’s principal commercial products in genomic sequencing and helps sustain its dominance in global research and clinical genomics markets.